The FASEB Journal, Vol 8, 401-407, Copyright © 1994 by The Federation of American Societies for Experimental Biology

REVIEWS

Angiogenesis and colonization in the tumor metastatic process: basic and applied advances

D Weinstat-Saslow and PS Steeg
Laboratory of Pathology, National Cancer Institute, Bethesda, Maryland 20892.

Tumor metastasis is a major cause of death for cancer patients. This review proposes that the final steps in the development of a distant metastasis may be the most productive targets for clinical development. It cannot be guaranteed that, in "metastasis-free" patients, tumor cells have not invaded out of the primary lesion, intravasated and extravasated from the circulatory system, and are sitting at distant sites as occult micrometastases. The remaining processes involved in outgrowth at metastatic sites, colonization and angiogenesis, are reviewed. Colonization is thought to be accomplished by clonally dominant cell populations through progressive independence from exogenous growth factors, production of growth factors, and stimulatory proliferative responses to traditionally inhibitory cytokines. Therapeutic efforts aimed at interrupting the switch in tumor cell responsiveness to cytokines, rather than to any one specific cytokine, may be most successful at inhibiting metastatic colonization. Angiogenesis has been demonstrated to be directly or indirectly induced by a plethora of cytokines. Partial suppression of neovascularization can be achieved in tissue culture and animal models using various natural and pharmaceutical angiostatic agents. However, as with clonal dominance, such agents must be able to suppress the redundant effects of angiogenesis-promoting factors. This review discusses the current literature on colonization and angiogenesis, emphasizing its underlying mechanisms and potential therapeutic applications.

This article has been cited by other articles:

				T. Kakinuma and S. T. Hwang Chemokines, chemokine receptors, and cancer metastasis J. Leukoc. Biol., April 1, 2006; 79(4): 639 - 651. [Abstract] [Full Text] [PDF]

				F. Ou-Yang, K.-L. Lan, C.-T. Chen, J.-C. Liu, C.-L. Weng, C.-K. Chou, X. Xie, J.-Y. Hung, Y. Wei, G. N. Hortobagyi, et al. Endostatin-Cytosine Deaminase Fusion Protein Suppresses Tumor Growth by Targeting Neovascular Endothelial Cells Cancer Res., January 1, 2006; 66(1): 378 - 384. [Abstract] [Full Text] [PDF]

				P. Traxler, P. R. Allegrini, R. Brandt, J. Brueggen, R. Cozens, D. Fabbro, K. Grosios, H. A. Lane, P. McSheehy, J. Mestan, et al. AEE788: A Dual Family Epidermal Growth Factor Receptor/ErbB2 and Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor with Antitumor and Antiangiogenic Activity Cancer Res., July 15, 2004; 64(14): 4931 - 4941. [Abstract] [Full Text] [PDF]

				S.-H. Tseng, S.-M. Lin, J.-C. Chen, Y.-H. Su, H.-Y. Huang, C.-K. Chen, P.-Y. Lin, and Y. Chen Resveratrol Suppresses the Angiogenesis and Tumor Growth of Gliomas in Rats Clin. Cancer Res., March 15, 2004; 10(6): 2190 - 2202. [Abstract] [Full Text] [PDF]

				Y. Ren, R. T.-P. Poon, H.-T. Tsui, W.-H. Chen, Z. Li, C. Lau, W.-C. Yu, and S.-T. Fan Interleukin-8 Serum Levels in Patients with Hepatocellular Carcinoma: Correlations with Clinicopathological Features and Prognosis Clin. Cancer Res., December 1, 2003; 9(16): 5996 - 6001. [Abstract] [Full Text] [PDF]

				M. GOTTE Syndecans in inflammation FASEB J, April 1, 2003; 17(6): 575 - 591. [Abstract] [Full Text] [PDF]

				M. Gotte, A. M. Joussen, C. Klein, P. Andre, D. D. Wagner, M. T. Hinkes, B. Kirchhof, A. P. Adamis, and M. Bernfield Role of Syndecan-1 in Leukocyte-Endothelial Interactions in the Ocular Vasculature Invest. Ophthalmol. Vis. Sci., April 1, 2002; 43(4): 1135 - 1141. [Abstract] [Full Text] [PDF]

				M. D. Cameron, E. E. Schmidt, N. Kerkvliet, K. V. Nadkarni, V. L. Morris, A. C. Groom, A. F. Chambers, and I. C. MacDonald Temporal Progression of Metastasis in Lung: Cell Survival, Dormancy, and Location Dependence of Metastatic Inefficiency Cancer Res., May 1, 2000; 60(9): 2541 - 2546. [Abstract] [Full Text]

				D. R. Welch and C. W. Rinker-Schaeffer What Defines a Useful Marker of Metastasis in Human Cancer? J Natl Cancer Inst, August 18, 1999; 91(16): 1351 - 1353. [Full Text] [PDF]

				K. Yonekura, Y. Basaki, L. Chikahisa, S. Okabe, A. Hashimoto, K. Miyadera, K. Wierzba, and Y. Yamada UFT and Its Metabolites Inhibit the Angiogenesis Induced by Murine Renal Cell Carcinoma, as Determined by a Dorsal Air Sac Assay in Mice Clin. Cancer Res., August 1, 1999; 5(8): 2185 - 2191. [Abstract] [Full Text] [PDF]

				E. R. Sauter, M. Nesbit, J. C. Watson, A. Klein-Szanto, S. Litwin, and M. Herlyn Vascular Endothelial Growth Factor Is a Marker of Tumor Invasion and Metastasis in Squamous Cell Carcinomas of the Head and Neck Clin. Cancer Res., April 1, 1999; 5(4): 775 - 782. [Abstract] [Full Text] [PDF]

				G. Naumov, S. Wilson, I. MacDonald, E. Schmidt, V. Morris, A. Groom, R. Hoffman, and A. Chambers Cellular expression of green fluorescent protein, coupled with high-resolution in vivo videomicroscopy, to monitor steps in tumor metastasis J. Cell Sci., January 6, 1999; 112(12): 1835 - 1842. [Abstract] [PDF]

				G. Montrucchio, A. Sapino, B. Bussolati, G. Ghisolfi, S. Rizea-Savu, L. Silvestro, E. Lupia, and G. Camussi Potential Angiogenic Role of Platelet-Activating Factor in Human Breast Cancer Am. J. Pathol., November 1, 1998; 153(5): 1589 - 1596. [Abstract] [Full Text] [PDF]

				C. H. Yeh, H.-C. Peng, and T.-F. Huang Accutin, a New Disintegrin, Inhibits Angiogenesis In Vitro and In Vivo by Acting as Integrin alpha vbeta 3 Antagonist and Inducing Apoptosis Blood, November 1, 1998; 92(9): 3268 - 3276. [Abstract] [Full Text] [PDF]

				K. J. Luzzi, I. C. MacDonald, E. E. Schmidt, N. Kerkvliet, V. L. Morris, A. F. Chambers, and A. C. Groom Multistep Nature of Metastatic Inefficiency : Dormancy of Solitary Cells after Successful Extravasation andLimited Survival of Early Micrometastases Am. J. Pathol., September 1, 1998; 153(3): 865 - 873. [Abstract] [Full Text] [PDF]

				K. R. Dover and A. W. Valley Review : Angiogenesis: A new target for antineoplastic therapy Journal of Oncology Pharmacy Practice, January 1, 1996; 2(1): 43 - 60. [Abstract] [PDF]

				M. Friedlander, P. C. Brooks, R. W. Shaffer, C. M. Kincaid, J. A. Varner, and D. A. Cheresh Definition of Two Angiogenic Pathways by Distinct alpha(v) Integrins Science, December 1, 1995; 270(5241): 1500 - 1502. [Abstract] [PDF]

				R. T. Raines, M. P. Toscano, D. M. Nierengarten, J. H. Ha, and R. Auerbach Replacing a Surface Loop Endows Ribonuclease A with Angiogenic Activity J. Biol. Chem., July 21, 1995; 270(29): 17180 - 17184. [Abstract] [Full Text] [PDF]

				M G Anderson, G L Perkins, P Chittick, R J Shrigley, and W A Johnson drifter, a Drosophila POU-domain transcription factor, is required for correct differentiation and migration of tracheal cells and midline glia. Genes & Dev., January 1, 1995; 9(1): 123 - 137. [Abstract] [PDF]

				J.W. Gray, C. Collins, I.C. Henderson, J. Isola, A. Kallioniemi, O.-P. Kallioniemi, H. Nakamura, D. Pinkel, T. Stokke, M. Tanner, et al. Molecular Cytogenetics of Human Breast Cancer Cold Spring Harb Symp Quant Biol, January 1, 1994; 59(0): 645 - 652. [Abstract] [PDF]